Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2010

View Archived Issues

Latrophilin-3 gene is linked to susceptibility to ADHD and response to stimulant medication

Scientists convert human fibroblasts directly to multipotent hematopoietic progenitors

New apoptosis-inducing molecules discovered

Tryptophan 5-hydroxylase 2 may be new target to treat depression

Fresolimumab improves symptoms of primary focal segmental glomerulosclerosis in phase I trial

CXR-1002 shows promising safety and antitumor activity in first-in-human trial in advanced cancer

Medgenics extends Factor VIII Biopump collaboration

Novel serotonin 5-HT6 receptor ligands identified by Abbott

MiStent drug-eluting coronary stent system advances into clinic

Banyu Pharma presents new antagonists of peptide P518 receptor

New inhibitors of dual specificity protein kinase TTK patented

New inhibitors of cell division protein kinase 4 claimed

Sanofi Pasteur begins phase II trial of ACAM-CDIFF vaccine

Worldwide rights to pegsiticase acquired by 3SBio from EnzymeRx

Transgenomic to purchase Clinical Data's diagnostic business

Merck & Co. reports phase III data on once-daily raltegravir in HIV-1

IntelGenx acquires rights to INT-0010 formulation of dronabinol

Hemispherx requests more to resubmit data to FDA for Ampligen NDA in chronic fatigue syndrome

FDA to review Spectrum Pharma's complete response regarding Fusilev sNDA

Lilly is recruiting healthy volunteers for first-in-human trial of LY-2979165

Nymox Pharma secures financing commitment

Eisai submits MAA for insomnia treatment SEP-190 in Japan

Thallion and LFB begin phase II trial of Shigamabs in STEC infections

Sucampo to update Japanese MAA for lubiprostone in chronic idiopathic constipation

Keryx's short-term phase III trial of Zerenex meets primary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...